15 Best Stocks to Buy According to Jim Simons’ Renaissance Technologies

Page 5 of 14

10. Gilead Sciences Inc. (NASDAQ:GILD)

Renaissance Technologies Q4 Stake: $492.3 million

Number of Hedge Fund Holders: 74

Gilead Sciences, Inc. (NASDAQ:GILD), a U.S. biopharmaceutical company headquartered in Foster City, California, focuses on developing antiviral treatments for illnesses such as COVID-19, hepatitis B and C, influenza, and HIV/AIDS.

For the first quarter of 2025, Gilead Sciences, Inc. (NASDAQ:GILD) reported total product sales of $6.6 billion, a 1% decrease year-over-year. Although sales of COVID-19 treatments declined, the company’s base business, excluding Veklury (remdesivir), grew 4% year-over-year to $6.3 billion, indicating the underlying strength of its core portfolio. HIV products remained the mainstay of Gilead’s operations, accounting for $4.6 billion in sales (70% of total revenue) and increasing by 6% year-over-year.

On May 7, Gilead Sciences, Inc. (NASDAQ:GILD) announced that it would invest an additional $11 billion in the United States to strengthen its domestic manufacturing and research capabilities, becoming one of the latest companies to reveal spending plans in response to President Donald Trump’s tariff policy. According to the pharmaceutical company, the new investments will augment a $21 billion budget already set aside to support U.S. manufacturing and R&D through 2030. These expenditures will be allocated toward upgrading three existing locations, constructing three new facilities, and acquiring new technology.

ClearBridge Value Strategy stated the following regarding Gilead Sciences, Inc. (NASDAQ:GILD) in its Q1 2025 investor letter:

“Health care stocks populated our top performers for the quarter. Biopharmaceutical company Gilead Sciences, Inc. (NASDAQ:GILD) announced strong fourth-quarter earnings growth and also rose both on news that its HIV prevention treatment drug Lenacapavir had been filed for U.S. approval, with an anticipated launch scheduled for mid-2025, and on positive reception to its cirrhosis of the liver treatment Livdelzi in its first full quarter.”

Page 5 of 14